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Summary Lometrexol (5,10-dideazatetrahydrofolic acid; DDATHF), is a specific inhibitor of glycinamider-
ibonucleosyl (GAR) transformylase with anti-tumour activity in murine and human carcinomas. The
cytotoxicity activity of DDATHF was evaluated in vitro in NIH/3T3 cells transfected with human a-folate-
binding protein (FBP) complementary DNA to examine the role of the receptor. In FBP-transfected NIH/3T3
(FBP-tNIH/3T3) cells, which internalised about three times more 5-methyltetrahydrofolic acid than the mock-
transfected cells, the cytotoxic potential of DDATHF showed a clear increase. Subsequently, we analysed four
ovarian carcinoma cell lines (OVCAR3, IGROVI, SKOV3 and SW626) expressing different amounts of FBP.
Cells were conditioned to grow in medium depleted of folic acid then tested by MOvl8 and folic acid binding.
Only SKOV3 and SW626 cells grown in folic acid-depleted medium showed increased FBP expression, about 3-
and 8-fold respectively. The cytotoxic potential of DDATHF was evaluated by a standard clonogenic assay. In
a medium containing 2.27 ,IM folic acid the DDATHF IC50 values were 50 nm on OVCAR3, 500 nm on
SW626 and 1000 nm on IGROVI. In folic acid-free medium IC50 values were 2 nm on OVCAR3 and SW626
and 40 nm on IGROVI. Only on SKOV3 cells was DDATHF cytotoxicity the same regardless of the amount
of folic acid in the medium (IC50 8 nM). Thus, DDATHF did not inhibit the growth of IGROVI cells depleted
of folic acid after stripping FBP with phosphatidylinositol-phospholipase C, even at a dose toxic for cells
constitutively expressing FBP. Although FBP expression is certainly one of the parameters affecting drug
toxicity, taken alone it is not a sufficiently reliable predictor of cancer cell sensitivity to DDATHF.
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5,10-Didzatetrahydrofolic acid (DDATHF, Lometrexol) is
representative of a new class of antimetabolites designed to
inhibit folate-dependent enzymes other than dihydrofolate
reductase. Its mode of action is related to the inhibition of
glycinamideribonucleosyl (GAR) transformylase, a key
enzyme in the de novo synthesis of purines (Moran et al.,
1985; Beardsley et al., 1989; Taylor et al., 1989; Baldwin et
al., 1991) and it is under early clinical investigation in Europe
and in the USA (Muggia et al., 1990; Sessa et al., 1990;
Young et al., 1990; Ray et al., 1993; Humphreys et al., 1995).
Aspects of the cellular pharmacology of DDATHF have
been investigated in detail; it causes no detectable DNA
breaks even after 48 h continuous exposure and its cytotoxic
potential can be modulated by folic and folinic acid (Erba et
al., 1994); DDATHF prevents the proliferation of tumour
cells in vitro (Taylor et al., 1989; Beardsley et al., 1989;
Moran et al., 1989; Erba et al., 1994) and in vivo (Beardsley
et al., 1986; Shih et al., 1988; Alati et al., 1992; Grindley et
al., 1992), and causes purine nucleotide depletion (Beardsley
et al., 1989). Because of its chemical homology to folates, the
drug is taken up by cells through physiological folate uptake
mechanisms (reviewed in Antony, 1992).
One of the major uptake systems utilised by eukaryotic
cells is the high-affinity folate receptor called folate-binding
protein (FBP). FBP is a family of related genes expressed at
different levels in different tissues (Ross et al., 1994;
Sadasivan et al., 1994). Three FBP isoforms have been
identified at the molecular level: (1) the a-isoform, which is
expressed at low levels in a few normal tissues and tends to
be elevated in some malignant tissues of epithelial origin; (2)
the 13-isoform, which is expressed at low to moderate levels in
all normal tissues and elevated in malignancies of non-
epithelial origin; and (3) the recently identified y-isoform,
which is present in certain carcinomas and in normal and
malignant hematopoietic cells. Ovarian carcinoma cells in
particular show a several-fold increase in a-FBP expression.
Therefore, this oncotype could be considered a prime target
for DDATHF therapy.
The aim of this study was to investigate the cytotoxicity
potential of DDATHF as a function of FBP expression.
NIH/3T3 cells transfected with human a-FBP cDNA and, in
separate experiments, four ovarian carcinoma cell lines,
which constitutively express different amounts of FBP, were
grown in medium containing supra- and subphysiological
folate concentrations and analysed for their sensitivity to
DDATHF.
Materials and methods
Reagents
DDATHF was obtained from Eli Lilly (Indianapolis, IN,
USA). RPMI-1640 medium containing 2.27 ,uM folic acid,
custom-prepared folic acid-free RPMI-1640 medium, Dul-
becco's modified Eagle medium (DMEM) containing 9.2 ,UM
folic acid, folic acid-free DMEM medium, geneticin G418
sulphate and glutamine were all purchased from Gibco
Europe, Paisley, UK. Dialysed (cut-off 3500 Da) fetal bovine
serum (FBS, batch 669141) was from Biological Industries,
Israel. Recombinant phosphatidylinositol-phospholipase C
(PI-PLC) was purchased from Oxford GlycoSystems,
Abingdon, UK. Spectra/Por 3 (molecular weight cut-off,
3500 Da) membrane from Spectrum Medical Industries (Los
Angeles, CA, USA) was used as a dialysis bag. [3H]folic acid
(specific activity, 32 Ci mmol-1) was obtained from Amer-
sham, UK. 5-Methyl[3H]tetrahydrofolate (5-MTHF) (sp. act.
27 Ci mmol-') was obtained from Moravek Biochemicals,
Brea, CA, USA. Nunclon plastic flasks and Falcon plastic
Petri dishes used for tissue culture were from Nunc AG
(Roskilde, Denmark) and Becton Dickinson (Mountain View,
USA) respectively.
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Cells and culture conditions
Construction of the human FBP cDNA vector, transfection
procedures and cloning have been described in detail
(Bottero et al., 1993). NIH/3T3 cells, transfected with the
expression vector pcDNAIneo containing c-FBP cDNA or
with the vector alone (FBP-t and mock-t) were cultured in
DMEM containing 9.2 jgM folic acid supplemented with
10% FBS and 800 ,ugml-1 geneticin G418 sulphate. NIH/
3T3 cells were conditioned to grow in DMEM supplemented
with 10% dialysed FBS or else were grown in custom-
prepared folic acid-free medium supplemented with 10%
dialysed FBS.
The following human ovarian carcinoma cell lines were
used: IGROVI (Benard et al., 1985), SKOV3 (Fogh et al.,
1977), OVCAR3 (Hamilton et al., 1983) and SW626 (Fogh et
al., 1977). These cells were grown as monolayers in RPMI
supplemented with 10% dialysed FBS or in custom-prepared
folic acid-free medium supplemented with 10% dialysed FBS.
All the cell lines were routinely checked for mycoplasma
contamination following the American Type Culture Collec-
tion protocol and found to be negative.
5-MTHF uptake
To evaluate 5-MTHF uptake, FBP-t and mock-t NIH/3T3
were seeded in T-25 flasks and grown for 4 days in DMEM
without folic acid. On day 4 the medium was removed and
cells were washed twice with PBS. Cells were further incubated
for 4 h at 4°C or 37°C with 1 ml 10 nM [3H]5-MTHF in PBS
containing 50 nM HEPES. After incubation, the medium was
aspirated and cells were washed twice with PBS. [3H]5-MTHF
was quantitated in cell membrane and cytoplasmic fractions
prepared essentially as described by Kamen et al., (1989).
Briefly, cells were lysed by freeze-thawing in hypotonic buffer
(10 mm Tris-HCl, 1 mM EDTA, pH 8, 0.02 mg ml1-
aproinin, 0.02 mg ml-' leupeptin, 10 jgM 5-MTHF, 2 ml per
T-25 flask) and membranes were separated from cell
cytoplasm by centrifugation for 1 h at 40 000 r.p.m. in a Ty
65 rotor (Beckman Instrument, Palo Alto, CA, USA).
Membrane fractions were resuspended in 10 mM Tris-HCl,
1 mM EDTA, pH 8 containing 0.5% SDS. Radioactivity was
measured by scintillation counting of aliquots of these
fractions. Cell number was determined in the trypsin EDTA
suspension of cells seeded and grown as described above.
Folic acid binding
Binding of [3H]folic acid was tested on cell lysates after
removing endogenous folate. Briefly, cells grown in medium
with or without folic acid were washed twice with PBS and
solubilised for 1 h in lysis buffer [50 mm Tris-HCl pH 7.4,
150 mM sodium chloride, 5 mM EDTA, 1.1% n-octylgluco-
side, 0.24 TIU ml-' aprotonin, 1% phenlymethylsulphonyl
fluoride (PMSF)] at 5 x 106 cells ml-'. Samples were
centrifuged for 10 min at 11 000 g and supernatants
recovered. To eliminate endogenous folate cell lysates were
treated for 30 min on ice with 100 mM acetic acid (pH 3) in
0.9% sodium chloride and centrifuged for 5 min at 1600 g on
a Sephadex G-25 microcolumn (0.9 ml bed volume)
equilibrated in lysis buffer containing 0.25% gelatin. Soluble
extracts were incubated with [3H]folic acid overnight at room
temperature and then applied to a spin column prepared as
described above. The eluted fractions were assessed for
radioactivity. Protein concentration was determined accord-
ing to Bradford (1976).
DDIRMA
Soluble proteins were analysed for FBP-immunoreactive
units by DDIRMA, using immobilised MOv18 and
['251]MOvl9 (Miotti et al., 1987). FBP-immunoreactive units
are defined as the amount of immunoreactivity in 1 ml of
the standard solution of IGROVI supernatant (Bottero et
al., 1993).
DDATHF treatment
DDATHF was dissolved in medium with dialysed serum
immediately before use and tested at concentrations between
0.01 nm and 10 pM, according to clinical and preclinical data
(Dr. Newell, personal communication; Erba et al., 1994).
DDATHF-induced inhibition of the growth of transfected
NIH/3T3 cells was determined by a standard growth
inhibition assay (Erba et al., 1992). Briefly, exponentially
growing cells in medium with or without folic acid were
treated with different concentrations of DDATHF for 24 h.
After treatment the drug-containing medium was removed,
cells were washed with PBS and fresh medium was provided.
Cells were counted every 24 h by standard trypsinisation,
using a Coulter counter model ZB coupled to a Channelyzer
256 (Coulter Electronics, Luton, UK). Results were
calculated as number of treated cells as a percentage of
control cells.
The effect of the drug on the human cell lines was
evaluated by a standard clonogenic assay (Erba et al., 1992).
Briefly, 103 cells were plated in 3 ml of medium in 60 mm
diameter Petri dishes. Cell viability was checked using
erythrosin B. After 24 h DDATHF treatment in medium
with or without folic acid the colonies were allowed to
develop for 14 days. Plating efficiency of untreated,
exponentially growing control cells was periodically checked
and found to be consistent. Colonies were stained with 1%
crystal violet solution in 20% ethanol and the number of
colonies and mean colony area were measured using the
Entry Level image analysis system (Immagini & Computer,
Rho, Italy). Background correction was performed and the
smallest control cell colony was taken as the cut-off point.
PI- PLC treatment
IGROVl cells were washed twice with prewarmed PBS and
incubated with 2 ml of PBS containing 0.2 U PI-PLC ml-1
for 4 h at 37°C in a carbon dioxide incubator with occasional
agitation. At the end of incubation cells were further
incubated for 4 h with 25 and 50 nM DDATHF and allowed
to recover in drug-free medium. MOv 18/19 status was
evaluated before, immediately after 4 h PI-PLC digestion, at
the end of DDATHF treatment and 24 h after recovery in
drug-free medium. The cytotoxic potential of DDATHF was
evaluated by counting the PI-PLC-treated and untreated
cells 24, 48 and 72 h after drug treatment.
Results
DDATHF cytotoxicity on FBP transfected cells
We have previously reported the biochemical characterisation
of NIH/3T3 transfected with a-FBP cDNA (Bottero et al.,
1993). In FBP-tNIH/3T3 cells, ax-FBP expression was about
30 times higher than in mock t-NIH/3T3 cells growing in
DMEM and the receptor actively internalised 5-MTHF
(Table I). When these cells were conditioned to grow in
DMEM without folic acid, FBP content, evaluated by MOv
18 binding, remained unchanged, cell growth was slightly
retarded but cell morphology was unaltered.
The cytotoxic. activity of DDATHF was investigated on
FBP-t and mock-tNIH/3T3 cells to examine the possible role
of the receptor. Cells grown in DMEM were conditioned to
grow in low-folate media by reducing the folic acid
concentration from 9.2 pM to 0.9 pM for at least six
Table I Uptake of [3H]5-MTHF by transfected NIH/3T3 cells
[3H]5-MTHF
(pmol Jo-6 cells)
Surface Internalised
Mock-tNIH/3T3 0.05 0.30
FBP-tNIH/3T3 0.17 0.80passages, then stepwise from 0.9 to 0.5 to 0.05 to 0.025 to
0.0125 pIM. Under low-folate conditions the cells grew
normally; the doubling time and cell morphology remained
unaffected. From the last passage, only FBP-tNIH/3T3 cells
were conditioned to grow in folic acid-free medium for at
least six passages, with dialysed FBS as the sole source of
folate. Since folic acid markedly reduces the anti-tumour
activity (Grindey et al., 1992; Erba et al., 1994), higher
concentrations of DDATHF were used to treat cells grown in
DMEM. In DMEM the cytotoxicity of DDATHF was
identical on mock-tNIH/3T3 and FBP-tNIH/3T3 cells
(Figure la and b). In DMEM without folic acid (Figure lc
and d) DDATHF did not reach 50% cytotoxicity on mock-
tNIH/3T3 cells even at 100 nM, whereas FBP-tNIH/3T3 cell
growth was reduced by 50% at 10 nM.
FBP expression and DDATHF cytotoxicity on ovarian
carcinoma cells
To assess the role of folic acid in the medium ovarian
carcinoma cells were grown in media containing progressively
lower folate concentration as described previously (Erba et
al., 1994).
FBP expression and modulation was quantitated on
lysates as ability to bind folic acid, after removing
endogenous folate and compared with MOvl8/MOvl9
reactivity (Table II). FBP expression in OVCAR3 and
IGROVI cells growing in folic acid-free medium respectively
decreased and increased by about 20%. Folic acid binding
and MOvl8/MOvl9 reactivity increased more than 3-fold in
SKOV3 cells growing in folic acid-free RPMI. SW626 cells
expressed detectable amounts of FBP only in folic acid-free
medium and folic acid binding increased about 8-fold.
DDATHF cytotoxicity was evaluated in the four ovarian
carcinoma cell lines with or without folic acid in the medium
by a standard clonogenic assay (Figure 2). Dose-response
curves showed a marked increase in the cytotoxic potential of
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DDATHF when OVCAR3, IGROVI and SW626 cells were
treated in medium without folic acid. In a medium containing
2.27 ,UM folic acid, the DDATHF IC5s values were 50 nM on
OVCAR3, 500 nM on SW626 and 1000 nM on IGROVI. In
folic acid-free medium IC50 values were 2 nM on OVCAR3
and SW626 and 40 nM on IGROVI. Only on SKOV3 cells
was DDATHF cytotoxicity the same regardless of the
amount of folic acid in the medium (IC50 8 nM). Therefore
the IC50 values did not appear to be directly related to the
number of FBP molecules expressed on the cell membrane
(see Table II).
DDATHF cytotoxicity on FBP-stripped ovarian cancer cells
To confirm that FBP was responsible for DDATHF
internalisation an experiment was designed to compare drug
cytotoxicity in the same cell line after removal of FBP from
the membrane. IGROVI cells grown in folic acid-free RPMI,
in which the cytotoxic potential of DDATHF was greatly
increased (Figure 2), were treated with PI-PLC, to which the
Table II Expression of FBP on carcinoma cell lines evaluated for
folic acid binding and DDIRMA reactivity
[3H]-folic acid MOv18/MOv19
Cell line (pmol mg ') (Immunoreactive units mg- )
OVCAR3 25.00 5.90
OVCAR3a 21.00 5.00
IGROVI 6.80 1.40
IGROVla 7.20 1.80
SKOV3 0.70 0.20
SKOV3a 2.40 0.80
SW626 0.20 -
SW626a 1.60 0.26
aFolic acid-free medium. -, Under the level ofdetectability.
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Figure 1 Time course of cell growth inhibition induced in mock-t and FBP-tNIH/3T3 growing in medium with 9.2pM folic acid (a
and b respectively) or without folic acid (c and d respectively). (a and b) -O-, 100nM; ---, 500nM; -LI-, 1000nM; -M-, 2500nM; -A-,
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Figure 2 Inhibition of clonogenicity of OVCAR3 (a), IGROVI (b), SKOV3 (c) and SW626 (d) cells growing in medium containing
2.2 pM folic acid (O) or without folic acid (0) by 24h DDATHF treatment. Clonogenic potential of exponentially growing
untreated cells ranged between 85% and 90% of the cells plated, which was normalised to 100%. Data are representative of at least
three independent experiments; each point is the mean of three experiments (+S.E.).
FBP of these cells is highly sensitive (Miotti et al., 1992).
Figure 3 shows that a 2 h digestion with PI-PLC reduced
FBP expression to near-negative control levels. At 4 h of
recovery (histogram C), cells began to express FBP again.
After 24 h (histogram D), FBP expression had increased
significantly but some of the cells were still negative. We then
did a 4 h DDATHF treatment immediately after PI-PLC
digestion on FBP-stripped IGROVI growing in folic acid-free
RPMI (Figure 4). The cytotoxic potential of DDATHF was
not detectable, even at the maximal dose tested in IGROVI
Figure 3 Flow cytometric evaluation of FBP expression by
MOv18 antibody in IGROVI cells growing in medium without
folic acid. A, untreated cells; B, cells immediately after PI-PLC
digestion; C, cells after 4h of recovery from PI-PLC digestion;
D, cells after 24h of recovery from PI-PLC digestion.
cells lacking membrane FBP. By contrast, untreated cells
constitutively expressing FBP showed a dose-dependent
inhibition soon after DDATHF treatment.
Discussion
The present study shows that FBP plays an important role in
the cytotoxicity of DDATHF since NIH/3T3 cells transfected
with a-FBP cDNA become approximately 10-fold more
sensitive to the drug than the mock-tNIH/3T3 cells when
grown in medium with low folic acid content. DDATHF has
been reported to use both the classical reduced folate carrier
and FBP (Jansen et al., 1991; Westerhof et al., 1991; Pizzorno
et al., 1993). In FBP-tNIH/3T3 cells folic acid acts as a tight
binding inhibitor of receptor-coupled processes and in folic
acid-free DMEM the cytotoxic potential of DDATHF was
observed only at concentrations higher than 500 nM. On the
other hand, in medium without folic acid only FBP-tNIH/
3T3 cells were sensitive at 10 nM of the drug.
Since FBP appears to be highly expressed in human
ovarian cancer, it was of interest to investigate the
cytotoxicity of DDATHF in cells derived from this type of
tumour and to evaluate whether the modulation of the
expression of FBP modified the drug cytotoxicity in these cell
lines.
In two out of four cell lines, OVCAR3 and IGROVI, the
low concentration of folic acid did not induce any relevant
change in FBP expression determined either using MOv18
and MOvl9 antibody or as folic acid binding. However,
under those conditions, there was an increase in DDATHF
cytotoxicity in both cell lines, suggesting that folic acid bound
to FBP reduces the anti-tumour activity of the drug. These
data are consistent with earlier observations that the presence
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DDATHF (nM)of folic acid and folinic acid markedly reduce the cytotoxicity
of DDATHF in vitro (Erba et al., 1994), and in vivo the
toxicity was reversed and DDATHF anti-tumour activity
retained only in animals that had received folic acid before
DDATHF (Alati et al., 1992; Grindey et al., 1992).
In the other two cell lines, SKOV3 and SW626, there was
a clear-cut increase in FBP expression when the cells were
maintained in medium with a low folic acid concentration.
SKOV3 cells behave somewhat differently to the other cell
lines. Although DDATHF cytotoxicity on these cells was the
same regardless of the folic acid concentration, FBP
expression increased about 3-fold when SKOV3 cells were
grown in medium without folic acid. FBP might not be the
molecule responsible for drug uptake in this cell line. The
mechanism of folate internalisation in SKOV3 cells might
resemble that proposed for the MA104 cell line, in which
FBP only binds folate, with internalisation through the cell
membrane dependent on a carrier molecule (Kamen et al.,
1989). Unfortunately, experiments on FBP-stripped cells were
not possible on SKOV3 cells because the FBP expressed on
these cells shows very low sensitivity to PI-PLC treatment
(Miotti et al., 1992).
IC50 values did not appear to be directly related to the
number of FBP molecules expressed on the cell membrane.
OVCAR3 and SW626 cells, which expressed high and low
levels of FBP respectively, have similar IC50 values, whereas
IGROVI cells, which expressed FBP at levels 3-fold lower
than OVCAR3, had higher IC50 values than those cells. Thus,
FBP expression might not be the only variant involved in
DDATHF cytotoxicity.
Among the ovarian cancer cell lines investigated only
SW626 cells showed an association between FBP expression
and increased cytotoxicity of DDATHF. Notably, only in
SW626 cells FBP expression was undetectable when the cells
were maintained in folic acid-rich medium. Therefore the
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different cytotoxicity of DDATHF against SW626 in medium
with or without folic acid was demonstrated when cells were
either not expressing or expressing FBP. This change, from
no expression to expression was similar to that seen in mock-
t-NIH/3T3 and FBP-t-NIH/3T3 cells, in which a DDATHF
cytotoxicity increased significantly in parallel with the
expression of FBP. The association between lack of FBP
expression and a marked reduction in DDATHF cytotoxicity
was also demonstrated in IGROVI cells, which became
resistant to the antifolate after PI-PLC digestion.
Since it is well known that the reduced folate carrier is a
transmembrane glycoprotein not sensitive to PI-PLC
treatment, we suggest that the major protein involved is the
FBP.
Together these studies, particularly those comparing mock
and mFBP transfected NIH/3T3 cells and on IGROVI
stripped of membrane FBP, indicate the importance of mFBP
for the cytotoxicity of DDATHF. However, the data
obtained in the four ovarian cancer cell lines suggest that
other factors are implicated too, as there was no correlation
between the levels of FBP and the ICso. Because no
radiolabelled DDATHF of high specific activity was
available, it was not possible to measure intracellular
DDATHF uptake. Therefore, one of the possibilities is that
the different cytotoxicity is, at least in part, related to
different efficiency of the reduced folate carrier.
Analysis of 5-MTHF internalisation in the present cell
lines, as well as in other ovarian carcinoma cell lines,
indicates that FBP is not functional in some of them (S
Miotti, personal communication) and that the expression of
the reduced folate carrier remains unaltered in folate-depleted
medium.
A further important cellular determinant of DDATHF
cytotoxicity is accumulation of the polyglutamate forms of
the drug, which is related to the activity of folylpolygluta-
mate syntethase, together with altered reduced folate pools
and increaed y-glutamyl hydrolase activity (Pizzorno et al.,
1995). Polyglutamylated derivatives of DDATHF are not
only retained longer in cells but are also much more potent
inhibitors of GAR transformylase which is the main
biochemical target of this antifolate (Moran et al., 1989;
Pizzorno et al., 1991).
In conclusion, although FBP expression appears to be an
important factor for the cytotoxicity of DDATHF, the data
obtained in these ovarian cancer cell lines suggest that FBP in
human tumours cannot be considered a sufficiently reliable
predictor of the sensitivity to DDATHF. Thus, FBP cannot
be the only parameter used for the selection of potentially
responsive patients to antifolate drugs.
Abbreviations
BSA, bovine serum albumin; cDNA, complementary DNA;
DDATHF, 5,10-dideazatetrahydrofolic acid; DMEM, Dulbecco's
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Figure 4 Inhibition of cell growth by DDATHF after stripping
cells of FBP on IGROVI cells undigested (open symbols) or Pl-
PLC-digested (closed symbol) were treated with 20 (0) or 50 (LI)
nM DDATHF for 4h. Cell growth was determined 24, 48 and
72h after drug washout.
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